Instrument Inactif

Autres langues Spring Bank Pharmaceuticals, Inc.

Actions

SBPH

US8494311017

Autres langues

25/11/20	F-STAR THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
24/11/20	Spring Bank Pharmaceuticals : F-star Therapeutics Announces Approval of Clinical Trial Application for FS222
22/11/20	Spring Bank Pharmaceuticals : F-star Therapeutics Completes Combination with Spring Bank Pharmaceuticals
22/11/20	Spring Bank Pharmaceuticals : F-star Therapeutics to Present New Clinical and Mechanistic Data on its LAG-3/PD-L1 Tetravalent Bispecific Antibody, FS118, at the SITC 2020 Virtual Annual Meeting
20/11/20	F-STAR THERAPEUTICS, INC. : Completion of Acquisition or Disposition of Assets, Material Modification to Rights of Security Holders, Changes in Registrant's Certifying Accountant, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)
20/11/20	Spring Bank Pharmaceuticals, Inc. has Changed its Name to F-star Therapeutics, Inc
20/11/20	Spring Bank Pharmaceuticals : Stockholders Approve Combination with F-star Therapeutics
20/11/20	F-Star Therapeutics Limited completed the acquisition of Spring Bank Pharmaceuticals, Inc. in a reverse merger transaction.
19/11/20	Spring Bank Pharmaceuticals : Stockholders Approve Combination with F-star Therapeutics
19/11/20	Spring Bank Pharmaceuticals Stockholders Approve Combination with F-star Therapeutics
09/11/20	SPRING BANK PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
06/11/20	Spring Bank Pharmaceuticals : Announces Special Dividend of Contingent Value Rights
06/11/20	Spring Bank Pharmaceuticals Announces Special Dividend of Contingent Value Rights
03/11/20	SPRING BANK PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
03/11/20	Spring Bank Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020
03/11/20	Spring Bank Pharmaceuticals : Announces Poster Presentation at the 2020 Society for Immunotherapy of Cancer Annual Meeting
02/11/20	Spring Bank Announces Poster Presentation at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
02/11/20	Spring Bank Pharmaceuticals : Announces Poster Presentation at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
10/08/20	Spring Bank Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020
10/08/20	SPRING BANK PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
10/08/20	Spring Bank Pharmaceuticals Reports Second Quarter 2020 Financial and Operational Results
03/08/20	SPRING BANK ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of SBPH and Encourages Investors to Contact the Firm
31/07/20	SPRING BANK PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
30/07/20	SPRING BANK PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
29/07/20	Spring Bank Pharmaceuticals and F-star Therapeutics Agree to Combine to Pursue Mission of Creating Next Generation Immunotherapies